Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry

Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry

<b>Background:</b> The therapeutic effects of oral anticoagulant drugs for nonvalvular atrial fibrillation (NVAF) suggest that the three factor Xa (FXa) inhibitors may have distinct safety profiles, though this is not yet fully conclusive. This study investigated the current dosing of ri...

Full description

Saved in:
Bibliographic Details
Main Authors: Michihiro Suwa, Isao Morii, Masaya Kino, Yumie Matsui, Masahiro Yoshinaga, Hiroki Takahashi, Masahiko Takagi, Akira Yoshida, Minoru Ichikawa, Osamu Nakajima, Mitsuhiro Tanimura, Hisashi Shimoyama, Hiroyuki Saitoh, Isao Sasaki, Takeshi Suzuki, Satoshi Uemae
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Pharmaceuticals
Subjects:
anticoagulation monitoring
apixaban
atrial fibrillation
edoxaban
on-label dosing
rivaroxaban
Online Access:https://www.mdpi.com/1424-8247/17/11/1431
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items